Infection by the respiratory syncytial virus in infants and young children at high risk (Q36112917)

12 August 2017

1 reference

title

Infection by the respiratory syncytial virus in infants and young children at high risk (English)

1 reference

12 August 2017

Damien Bonnet

1

1 reference

12 August 2017

Achim A Schmaltz

series ordinal

2

1 reference

12 August 2017

Timothy F Feltes

series ordinal

3

1 reference

12 August 2017

publication date

1 June 2005

1 reference

12 August 2017

published in

Cardiology in the Young

1 reference

12 August 2017

volume

15

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

256-265

1 reference

Long-term prospective study in children after respiratory syncytial virus infection

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Rates of hospitalization for respiratory syncytial virus infection among children in medicaid

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Survival with congenital heart disease and need for follow up in adult life

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Effectiveness of drug therapies to treat or prevent respiratory syncytial virus infection-related morbidity

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Mortality associated with influenza and respiratory syncytial virus in the United States

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Epidemiologic and clinical evidence of a respiratory syncytial virus-reactive airway disease link

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Recovery of cytopathogenic agent from chimpanzees with coryza

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7.

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Nosocomial respiratory syncytial virus: a threat in the modern neonatal intensive care unit

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

High risk of nosocomial-acquired RSV infection in children with congenital heart disease

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

The European Forum for Clinical Management: prophylaxis against the respiratory syncytial virus in infants and young children with congenital cardiac disease.

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Community and nosocomially acquired respiratory syncytial virus infection in a German paediatric hospital from 1988 to 1999.

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Respiratory syncytial virus vaccine development

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV.

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Future directions in vaccine prevention of respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Nosocomial respiratory syncytial virus infection in neonatal units in the United Kingdom.

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Respiratory syncytial virus morbidity and mortality estimates in congenital heart disease patients: a recent experience

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Respiratory syncytial viral infection in infants with congenital heart disease

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Acute and long-term effects of infection by the respiratory syncytial virus in children with congenital cardiac malformations

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999.

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Treatment and prevention of respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Respiratory syncytial virus in patients with congenital heart disease: a contemporary look at epidemiology and success of preoperative screening

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Incidence of congenital heart disease: I. Postnatal incidence.

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Respiratory syncytial virus: the virus, the disease and the immune response

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Recovery of respiratory syncytial virus from stethoscopes by conventional viral culture and polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Respiratory syncytial virus puzzle: clinical features, pathophysiology, treatment, and prevention

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

The Complex Relationship between Respiratory Syncytial Virus and Allergy in Lung Disease

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Immunoprophylaxis of respiratory syncytial virus: global experience

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Incidence of respiratory syncytial virus-positive hospitalizations in Germany.

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

National surveillance for respiratory syncytial virus, United States, 1985-1990.

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

[Use of palivizumab for the prevention of respiratory syncytial virus infections in children with congenital heart disease. Recommendations from the French Paediatric Cardiac Society]

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Risk of primary infection and reinfection with respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Palivizumab in the prevention of respiratory syncytial virus disease

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS1047951105000545

7 January 2021

10.1017/S1047951105000545

Identifiers

DOI

1 reference

12 August 2017

1 reference